US EditionPublished • loading... • Updated
Adaptimmune Announces Changes to Board and Executive Leadership Team
Summary by Kingston Whig-Standard
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Adaptimmune reports changes to BOD and leadership team - BioTuesdays
Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository Shares (ADSs) from Nasdaq on October 28, 2025. The company stated that Christopher Hill, current CFO of Adaptimmune, has been appointed CEO and a director, succeeding Andrew Rawcliffe. Mr. Rawcliffe and William Bertrand, formerly CO…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
